Comparative Pharmacology
Head-to-head clinical analysis: NORLESTRIN FE 1 50 versus TAYTULLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORLESTRIN FE 1 50 versus TAYTULLA.
NORLESTRIN FE 1/50 vs TAYTULLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and norethindrone acetate provides negative feedback on gonadotropin release, suppressing ovulation. Also causes cervical mucus thickening and endometrial thinning.
Combination of drospirenone, a spironolactone analog with antimineralocorticoid and antiandrogenic activity, and ethinyl estradiol, an estrogen. Suppresses gonadotropins, primarily luteinizing hormone, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.
One tablet (norethindrone 1 mg and ethinyl estradiol 50 mcg plus ferrous fumarate 75 mg) orally once daily for 28 days, with 21 active tablets and 7 placebo tablets.
One capsule orally once daily for 24 weeks.
None Documented
None Documented
Norethindrone: 5-12 hours (mean 8 hours). Ethinyl estradiol: 11-16 hours. Clinical context: Steady state reached in 5-7 days.
Terminal elimination half-life: 30 hours. Provides once-daily dosing with steady-state achieved after 7 days.
Norethindrone: 20% renal, 80% fecal. Ethinyl estradiol: 40% renal, 60% fecal.
Renal: ~60% as unchanged drug; Fecal: ~40% as metabolites and unchanged drug.
Category C
Category C
Oral Contraceptive
Oral Contraceptive